meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all population
1
mUC - M - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs BSC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab based treatment
avelumab alone
mUC - M - PDL1 positive
1
Comparator:
vs BSC;
Risk of bias:
low;
some concerns;
high;
NA;